Cargando…
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
SIMPLE SUMMARY: Solid tumor patients under active anticancer treatment are peculiarly affected by COVID-19 infection, given not only its ominous outcomes but also the need of disruptions of their rather strict therapeutic scheme. Thus, they have been globally prioritized for both primary and booster...
Autores principales: | Terpos, Evangelos, Liontos, Michalis, Fiste, Oraianthi, Zagouri, Flora, Briasoulis, Alexandros, Sklirou, Aimilia D., Markellos, Christos, Skafida, Efthymia, Papatheodoridi, Alkistis, Andrikopoulou, Angeliki, Koutsoukos, Konstantinos, Kaparelou, Maria, Iconomidou, Vassiliki A., Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179468/ https://www.ncbi.nlm.nih.gov/pubmed/35681774 http://dx.doi.org/10.3390/cancers14112796 |
Ejemplares similares
-
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022) -
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021) -
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021) -
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)